Pharmaceuticals company Lincoln Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights: Consolidated total income for Q4FY26 was Rs. 18,308.00 lakh, representing a YoY growth of 13.50% compared to Rs. 16,130.00 lakh in Q4FY25. Consolidated EBITDA for Q4FY26 stood at Rs. 2,066.00 lakh, up 4.13% YoY from Rs. 1,984.00 lakh. Consolidated net profit for Q4FY26 was Rs. 1,163.00 lakh, showing a YoY growth of 0.52% from Rs. 1,157.00 lakh. For the full year FY26, consolidated total income reached Rs. 70,448.00 lakh, a growth of 9.10% YoY compared to Rs. 64,571.00 lakh in FY25. Consolidated EBITDA for FY26 was reported at Rs. 13,114.00 lakh, growing 5.78% YoY from Rs. 12,397.00 lakh in FY25. Consolidated net profit for the full year FY26 reached Rs. 8,789.00 lakh, an increase of 6.74% over Rs. 8,235.00 lakh in FY25. Consolidated EPS for FY26 was reported at Rs. 43.88 per share. Standalone Financial Highlights: Revenue from operations for Q4FY26 stood at Rs. 18,727.73 lakh, representing a YoY increase of 11.35% compared to Rs. 16,818.31 lakh in Q4FY25 and a QoQ increase of 12.60% from Rs. 16,632.20 lakh in Q3FY26. Total income for Q4FY26 was Rs. 18,308.20 lakh, reflecting a YoY growth of 13.50% from Rs. 16,130.34 lakh and a QoQ growth of 0.89% from Rs. 18,146.75 lakh in Q3FY26. Net profit for Q4FY26 reached Rs. 1,163.46 lakh, which is a YoY increase of 0.52% compared to Rs. 1,157.50 lakh in Q4FY25, but a QoQ decline of 59.32% from Rs. 2,860.00 lakh in Q3FY26. For the full year FY26, revenue from operations reached Rs. 67,102.99 lakh, growing 7.67% YoY from Rs. 62,323.01 lakh in FY25. Annual total income for FY26 was Rs. 70,448.39 lakh, an increase of 9.10% over Rs. 64,570.72 lakh in FY25. Annual net profit for FY26 stood at Rs. 8,789.38 lakh, registering a YoY growth of 6.74% from Rs. 8,234.64 lakh in FY25. Earnings Per Share (EPS) for the full year FY26 was Rs. 43.88, compared to Rs. 41.11 in FY25. Business Highlights: Segment Performance: The company operates under a single business segment namely 'Pharmaceutical Business'. Dividend: The Board of Directors has recommended a dividend of 18%, which is Rs. 1.80 per share on the face value of Rs. 10 per share for the year ended March 31, 2026. Growth Targets: The company is targeting a revenue of Rs. 1,00,000 lakh within the next 3 years. It aims to achieve an annual growth rate of 15-18%, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. International Footprint: The company currently exports to 60+ countries and aims to expand this footprint to 90 countries over the next 2-3 years. It has recently entered the Canadian market and received approvals from TGA - Australia and EU GMP. Product Portfolio: The company has a robust portfolio of over 1,700 registered products, with an additional 700 products currently in the pipeline. Green Energy: The company is nearly a 100% green renewable energy consuming organization, supported by new solar plants at its Mehsana and Khatraj factories, alongside existing windmills. Investment Holdings: As of March 31, 2026, FII holding in the company stood at 5.20% and DII at 1.08%, compared to 5.00% FII holding as of March 31, 2025. Munjal Patel, Director, Lincoln Pharmaceuticals, said: "We are pleased to conclude FY26 on a strong note with healthy growth momentum driven by robust demand, improved operational efficiencies and consistent execution across markets. We remain focused on strengthening our product portfolio, expanding our domestic and international presence and investing in research and manufacturing capabilities. Backed by a debt-free balance sheet and strong fundamentals, we remain confident of sustaining profitable growth and creating long-term value for stakeholders." Result PDF

• Trendlyne
• 1 month ago

Income rose 13% to 183 crore (from 161 crore), while EBITDA increased 5% to 21 crore (from 20 crore)

• Business Line
• 1 month ago

Pharmaceuticals company Lincoln Pharmaceuticals announced Q3FY26 results Revenue: Rs 166.32 lakh against Rs 146.55 lakh during Q3FY25, change 13%. EBITDA: Rs 38.74 lakh against Rs 32.63 lakh during Q3FY25, change 19%. PBT: Rs 34.72 lakh against Rs 28.68 lakh during Q3FY25, change 21%. PAT: Rs 28.6 lakh against Rs 20.77 lakh during Q3FY25, change 38%. EPS: Rs 14.28 for Q3FY26. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: "We are pleased to deliver another strong quarter, reflecting consistent execution and resilient demand across all business verticals. We are strengthening our R&D; pipeline with over 100 new development programmes across multiple therapeutic segments and dosage forms, supported by bioequivalence studies and patent initiatives. These efforts reinforce our commitment to scientific innovation, unmet medical needs, and long-term. profitable growth. With a debt-free balance sheet, strong R&D; capabilities, and a healthy product pipeline, we remain confident of sustaining 15-18% annual growth and achieving our Rs 1,000 crore revenue target over the next three years." Result PDF

• Trendlyne
• 4 months 2 weeks ago